Literature DB >> 8491520

Congenital rubella syndrome after maternal reinfection.

B Weber1, G Enders, R Schlösser, B Wegerich, R Koenig, H Rabenau, H W Doerr.   

Abstract

This report concerns a case of congenital rubella syndrome (CRS) with atypical immune response affecting an infant whose mother had repeated evidence of immunity before pregnancy. Laboratory diagnosis of CRS could only clearly be achieved by virus isolation after the second month of life despite typical clinical features of CRS and multiple organ involvement. After the first month of age, low concentrations of specific IgM antibodies were revealed by ELISA and confirmed by a reference test system (IgM-specific haemagglutination inhibition assay). Persistent and increasing high levels of IgM antibodies were detected only after the 6th month of life. Later on IgG antibody levels decreased. Immunological investigations showed an IgG1-hypoglobulinaemia. The unusual feature of the present case report is not only the failure of the maternal rubella immunity to prevent CRS, but the defect of the child's immune system, probably attributable to congenital infection. As a consequence, laboratory diagnosis of CRS could not be achieved initially by the proved serological methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491520     DOI: 10.1007/BF01710747

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  29 in total

1.  Rubella reinfection in pregnancy followed by transmission to the fetus.

Authors:  T Eilard; O Strannegård
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

2.  Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic.

Authors:  D M Horstmann; H Liebhaber; G L Le Bouvier; D A Rosenberg; S B Halstead
Journal:  N Engl J Med       Date:  1970-10-08       Impact factor: 91.245

3.  Differential IgG avidity to rubella virus structural proteins.

Authors:  C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

4.  Fetal infection after maternal reinfection with rubella: criteria for defining reinfection.

Authors:  J M Best; J E Banatvala; P Morgan-Capner; E Miller
Journal:  BMJ       Date:  1989-09-23

5.  Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay.

Authors:  L A Mitchell; T Zhang; M Ho; D Décarie; A J Tingle; M Zrein; M Lacroix
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  Outcome of asymptomatic infection with rubella virus during pregnancy.

Authors:  J E Cradock-Watson; M K Ridehalgh; M J Anderson; J R Pattison
Journal:  J Hyg (Lond)       Date:  1981-10

7.  Reactivity of a recombinant rubella E1 antigen expressed in E. coli.

Authors:  P Londesborough; G Terry; L Ho-Terry
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Rubella vaccination: persistence of antibodies for up to 16 years.

Authors:  S O'Shea; J M Best; J E Banatvala; W C Marshall; J A Dudgeon
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-24

9.  Rubella-specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after intranasal challenge.

Authors:  G C Harcourt; J M Best; J E Banatvala
Journal:  J Infect Dis       Date:  1980-08       Impact factor: 5.226

10.  [Demonstration of Rubella-specific IgG and IgM antibody (sub) classes using the enzyme immunoassay (EIA)].

Authors:  H W Doerr; G Fleischer; M Wiesmann
Journal:  Immun Infekt       Date:  1984-02
View more
  2 in total

1.  Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR.

Authors:  M G Revello; F Baldanti; A Sarasini; M Zavattoni; M Torsellini; G Gerna
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 2.  Does Rubella Cause Autism: A 2015 Reappraisal?

Authors:  Jill Hutton
Journal:  Front Hum Neurosci       Date:  2016-02-01       Impact factor: 3.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.